Male breast cancer? What? Do they mean transgender? No! 😊
Male breast cancer is different from female breast cancer, but conventional treatment is the same until now!
"Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets ...
The researchers conducted the first whole genome sequencing analysis of male breast cancer, which looked at the complete DNA landscape of tumor samples from 10 patients. This is an important step in viewing breast cancer in men, which represents less than 1% of all breast cancer cases each year, as a unique disease. ...
the incidence in men has increased at a much faster rate than in women over the last 40 years. Also, most men are unaware of their risk, so they tend to be diagnosed at more advanced stages and have poorer treatment outcomes. ...
The good news is that cancer therapies are available to target the genetic variations identified in eight of the 10 men, opening new pathways to treatment. ..."
the incidence in men has increased at a much faster rate than in women over the last 40 years. Also, most men are unaware of their risk, so they tend to be diagnosed at more advanced stages and have poorer treatment outcomes. ...
The good news is that cancer therapies are available to target the genetic variations identified in eight of the 10 men, opening new pathways to treatment. ..."
From the abstract:
"The molecular characterization of male breast cancer (MaBC) has received limited attention in research, mostly due to its low incidence rate, accounting for only 0.5-1% of all reported cases of breast cancer each year. Managing MaBC presents significant challenges, with most treatment protocols being adapted from those developed for female breast cancer. Utilizing whole-genome sequencing (WGS) and state-of-the-art analyses, the genomic features of ten (n=10) MaBC cases were delineated and correlated with clinical and histopathological characteristics. Using fluorescence in situ hybridization (FISH), an additional cohort of 18 patients was interrogated to supplement WGS findings. The genomic landscape of MaBC uncovered significant genetic alterations that could influence diagnosis and treatment. We found common somatic mutations in key driver genes such as FAT1, GATA3, SMARCA4, and ARID2. Our study also mapped out structural variants (SVs) that impact cancer-associated genes like ARID1A, ESR1, GATA3, NTRK1, and NF1. Using a WGS-based classifier, homologous recombination deficiency (HRD) was identified in two cases, both presenting with deleterious variants in BRCA2. Noteworthy was the observation of FGFR1 amplification in 21% of cases. Altogether, we identified at least one potential therapeutic target in 8 of 10 cases, including high tumor mutational burden, FGFR1 amplification and HRD. Our study is the first WGS characterization of MaBC, which uncovered potentially relevant variants including structural events in cancer genes, HRD signatures, and germline pathogenic mutations. Our results demonstrate unique genetic markers and potential treatment targets in MaBC, thereby underlining the necessity of tailoring treatment strategies for this under-studied patient population. These WGS-based findings add to the growing knowledge of MaBC genomics and highlight the need to expand research on this type of cancer."
"The molecular characterization of male breast cancer (MaBC) has received limited attention in research, mostly due to its low incidence rate, accounting for only 0.5-1% of all reported cases of breast cancer each year. Managing MaBC presents significant challenges, with most treatment protocols being adapted from those developed for female breast cancer. Utilizing whole-genome sequencing (WGS) and state-of-the-art analyses, the genomic features of ten (n=10) MaBC cases were delineated and correlated with clinical and histopathological characteristics. Using fluorescence in situ hybridization (FISH), an additional cohort of 18 patients was interrogated to supplement WGS findings. The genomic landscape of MaBC uncovered significant genetic alterations that could influence diagnosis and treatment. We found common somatic mutations in key driver genes such as FAT1, GATA3, SMARCA4, and ARID2. Our study also mapped out structural variants (SVs) that impact cancer-associated genes like ARID1A, ESR1, GATA3, NTRK1, and NF1. Using a WGS-based classifier, homologous recombination deficiency (HRD) was identified in two cases, both presenting with deleterious variants in BRCA2. Noteworthy was the observation of FGFR1 amplification in 21% of cases. Altogether, we identified at least one potential therapeutic target in 8 of 10 cases, including high tumor mutational burden, FGFR1 amplification and HRD. Our study is the first WGS characterization of MaBC, which uncovered potentially relevant variants including structural events in cancer genes, HRD signatures, and germline pathogenic mutations. Our results demonstrate unique genetic markers and potential treatment targets in MaBC, thereby underlining the necessity of tailoring treatment strategies for this under-studied patient population. These WGS-based findings add to the growing knowledge of MaBC genomics and highlight the need to expand research on this type of cancer."
No comments:
Post a Comment